Home » Stocks » LYRA

Lyra Therapeutics, Inc. (LYRA)

Stock Price: $10.95 USD -0.01 (-0.09%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 140.11M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 12.92M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $10.95
Previous Close $10.96
Change ($) -0.01
Change (%) -0.09%
Day's Open 10.91
Day's Range 10.91 - 11.45
Day's Volume 16,092
52-Week Range 9.28 - 18.56

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 16 hours ago

LOS ANGELES--(BUSINESS WIRE)---- $LYRA #LYRA--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Lyra Therapeutics, Inc.

Business Wire - 2 days ago

LOS ANGELES--(BUSINESS WIRE)---- $LYRA #LYRA--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lyra Therapeutics, Inc.

Business Wire - 1 month ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics Announces Positive Topline Results for LANTERN Phase 2 Randomized Controlled Study of LYR-210 for the Treatment of CRS

Seeking Alpha - 1 month ago

Lyra is to report top line data of its Phase 2 Trial in December. All indications are the trial should be a success, and they have strong backing from Perceptive Advisors.

Business Wire - 2 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics to Participate in Fireside Chat at the Jefferies Virtual London Healthcare Conference

Business Wire - 2 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Business Wire - 2 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyra Therapeutics Appoints Nancy L. Snyderman To Its Board of Directors

GlobeNewsWire - 4 months ago

Two additional presentations highlight supporting data for LYR-210’s clinical program covering key clinical endpoints for CRS and Lyra’s XTreo™ drug release performance

GlobeNewsWire - 4 months ago

Three poster presentations to be featured at the 66th Annual Meeting of the American Rhinologic Society Three poster presentations to be featured at the 66th Annual Meeting of the American Rhi...

Seeking Alpha - 5 months ago

Lyra Therapeutics, Inc. (LYRA) CEO Maria Palasis on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

WATERTOWN, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel in...

GlobeNewsWire - 5 months ago

WATERTOWN, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel in...

GlobeNewsWire - 5 months ago

WATERTOWN, Mass., July 24, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel in...

Seeking Alpha - 6 months ago

Lyra Therapeutics: Advancing An Innovative Solution For Chronic Rhinosinusitis

GlobeNewsWire - 6 months ago

WATERTOWN, Mass., July 07, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel in...

Seeking Alpha - 7 months ago

Lyra Therapeutics completed its IPO in late-April selling 3.5m shares at a price of $16 - the higher end of expectations - to raise $56m.

GlobeNewsWire - 7 months ago

WATERTOWN, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel int...

Market Watch - 8 months ago

Shares of Lyra Therapeutics Inc., a biotech specializing in treatments for ear, nose and throat diseases, soared 32% in their trading debut Friday, after the company's initial public offering ...

24/7 Wall Street - 8 months ago

When a raging bull market dies and turns into a bear market with a deep recession in less than 45 days, things are not normal.

About LYRA

Lyra Therapeutics, a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210 and LYR-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. The company was forme... [Read more...]

Industry
Biotechnology
IPO Date
May 1, 2020
CEO
Dr. Maria Palasis Ph.D.
Employees
33
Stock Exchange
NASDAQ
Ticker Symbol
LYRA
Full Company Profile

Financial Performance

Financial Statements